À¦°óSMÉçÇø

Biomarker and Biopsy-Driven Research towards Personalized Medicine

The MCTRC, in partnership with the Quebec – Clinical Research Organization in Cancer (Q-CROC), implements investigator-initiated biopsy-driven translational research, via its clinical research infrastructure. The overall aim is to identify molecular signatures and mechanisms of resistance to particular treatment in the clinical setting. Researchers involved in the biomarker/biopsy-driven research group apply OMIC technologies to look at hundreds of thousands of genes, proteins and other compounds simultaneously to identify biomarkers and molecular signatures associated with disease type, stage and outcome of cancer treatment.

Theme leader:

Dr. Gerald Batist, Lady Davis Institute for Medical Research, À¦°óSMÉçÇø

Members:

Dr. Moulay Alaoui-Jamali, Lady Davis Institute for Medical Research, À¦°óSMÉçÇø

Dr. Sarit Assouline, Jewish General Hospital, À¦°óSMÉçÇø

Dr. Mark Basik, Lady Davis Institute for Medical Research, À¦°óSMÉçÇø

Dr. Christoph Borchers, Lady Davis Institute for Medical Research, À¦°óSMÉçÇø

Dr. Cristiano Ferrario, Jewish General Hospital, À¦°óSMÉçÇø

Dr. Walter Gotlieb, Lady Davis Institute for Medical Research, À¦°óSMÉçÇø

Dr. Celia Greenwood, Lady Davis Institute for Medical Research, À¦°óSMÉçÇø

Dr. Nathalie Johnson, Lady Davis Institute for Medical Research, À¦°óSMÉçÇø

Dr. Claudia Kleinman, Lady Davis Institute for Medical Research, À¦°óSMÉçÇø

Dr. Bernard Lesperance, Université de Montréal

Dr. Wilson Miller, Lady Davis Institute for Medical Research, À¦°óSMÉçÇø

Dr. Alan Spatz, Lady Davis Institute for Medical Research, À¦°óSMÉçÇø

Back to top